The findings, published in Science, suggest promising new approaches for treating chronic autoimmune conditions, including systemic lupus and autoimmune liver disease, the researchers said. Gut bacteria have been linked to a range of diseases, including autoimmune conditions characterized by immune system attacks of healthy tissue. To shed light on this link, a Yale research team focused on Enterococcus gallinarum, a bacterium they discovered is able to spontaneously “translocate” outside of the gut to lymph nodes, the liver, and the spleen. In models of genetically susceptible mice, the researchers observed that in tissues outside the gut, E. gallinarum initiated the production of auto-antibodies and inflammation — hallmarks of the autoimmune response. They confirmed the same mechanism of inflammation in cultured liver cells of healthy people, and the presence of this bacterium in the livers of patients with autoimmune disease. Through further experiments, the research team found that they could suppress autoimmunity in mice with an antibiotic or a vaccine aimed at E. gallinarum. With either approach, the researchers were able to suppress the growth of the bacterium in the tissues and blunt its effects on the immune system. “When we blocked the pathway leading to inflammation, we could reverse the effect of this bug on autoimmunity,” said senior author Martin Kriegel, M.D. “The vaccine against E. gallinarum was a specific approach, as vaccinations against other bacteria we investigated did not prevent mortality and autoimmunity,” he noted. The vaccine was delivered through injection in muscle to avoid targeting other bacteria that reside in the gut. While Kriegel and his colleagues plan further research on E. gallinarum and its mechanisms, the findings have relevance for systemic lupus and autoimmune liver disease, they said. “Treatment with an antibiotic and other approaches such as vaccination are promising ways to improve the lives of patients with autoimmune disease,” he said. Other authors are S. Manfredo-Vieira, M. Hiltensperger, V. Kumar, D. Zegarra-Ruiz, C. Dehner, N. Khan, F.R.C. Costa, E. Tiniakou, T. Greiling, W. Ruff, A. Barbieri, C. Kriegel, S.S. Mehta, J.R. Knight, D. Jain, and A.L. Goodman. This work was supported by grants from the National Institutes of Health, the Yale Rheumatic Diseases Research Core, the Yale Liver Center, Women’s Health Research at Yale, the O’Brien Center at Yale, the Arthritis National Research Foundation, the Arthritis Foundation, and the Lupus Research Alliance. S. Manfredo-Vieira and M.A. Kriegel hold a patent related to this discovery for treating autoimmune diseases by targeting gut bacteria. Reference: “Translocation of a gut pathobiont drives autoimmunity in mice and humans” by S. Manfredo Vieira, M. Hiltensperger, V. Kumar, D. Zegarra-Ruiz, C. Dehner, N. Khan, F. R. C. Costa, E. Tiniakou, T. Greiling, W. Ruff, A. Barbieri, C. Kriegel, S. S. Mehta, J. R. Knight, D. Jain, A. L. Goodman and M. A. Kriegel, 9 March 2018, Science.DOI: 10.1126/science.aar7201
